These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1477 related items for PubMed ID: 21752941

  • 1. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
    Tsujihata Y, Ito R, Suzuki M, Harada A, Negoro N, Yasuma T, Momose Y, Takeuchi K.
    J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
    [Abstract] [Full Text] [Related]

  • 2. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets.
    Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Johnson PR, Rorsman P.
    J Pharmacol Exp Ther; 2012 Feb; 340(2):483-9. PubMed ID: 22106100
    [Abstract] [Full Text] [Related]

  • 3. Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas.
    Ito R, Tsujihata Y, Suzuki M, Miyawaki K, Matsuda K, Takeuchi K.
    J Pharmacol Exp Ther; 2016 Apr; 357(1):217-27. PubMed ID: 26813930
    [Abstract] [Full Text] [Related]

  • 4. TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats.
    Ito R, Tsujihata Y, Matsuda-Nagasumi K, Mori I, Negoro N, Takeuchi K.
    Br J Pharmacol; 2013 Oct; 170(3):568-80. PubMed ID: 23848179
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
    Sasaki S, Kitamura S, Negoro N, Suzuki M, Tsujihata Y, Suzuki N, Santou T, Kanzaki N, Harada M, Tanaka Y, Kobayashi M, Tada N, Funami M, Tanaka T, Yamamoto Y, Fukatsu K, Yasuma T, Momose Y.
    J Med Chem; 2011 Mar 10; 54(5):1365-78. PubMed ID: 21319751
    [Abstract] [Full Text] [Related]

  • 6. Constitutively active heat shock factor 1 enhances glucose-driven insulin secretion.
    Uchiyama T, Tomono S, Utsugi T, Ohyama Y, Nakamura T, Tomura H, Kawazu S, Okajima F, Kurabayashi M.
    Metabolism; 2011 Jun 10; 60(6):789-98. PubMed ID: 20817212
    [Abstract] [Full Text] [Related]

  • 7. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
    Bazydlo-Guzenda K, Buda P, Matloka M, Mach M, Stelmach F, Dzida R, Smuga D, Hucz-Kalitowska J, Teska-Kaminska M, Vialichka V, Dubiel K, Kaminska B, Wieczorek M, Pieczykolan J.
    Mol Pharmacol; 2021 Oct 10; 100(4):335-347. PubMed ID: 34349026
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.
    Negoro N, Sasaki S, Mikami S, Ito M, Tsujihata Y, Ito R, Suzuki M, Takeuchi K, Suzuki N, Miyazaki J, Santou T, Odani T, Kanzaki N, Funami M, Morohashi A, Nonaka M, Matsunaga S, Yasuma T, Momose Y.
    J Med Chem; 2012 Apr 26; 55(8):3960-74. PubMed ID: 22490067
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes.
    Leifke E, Naik H, Wu J, Viswanathan P, Demanno D, Kipnes M, Vakilynejad M.
    Clin Pharmacol Ther; 2012 Jul 26; 92(1):29-39. PubMed ID: 22669289
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats.
    Gowda N, Dandu A, Singh J, Biswas S, Raghav V, Lakshmi MN, Shilpa PC, Sunil V, Reddy A, Sadasivuni M, Aparna K, Verma MK, Moolemath Y, Anup MO, Venkataranganna MV, Somesh BP, Jagannath MR.
    BMC Pharmacol Toxicol; 2013 May 21; 14():28. PubMed ID: 23692921
    [Abstract] [Full Text] [Related]

  • 17. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways.
    Wente W, Efanov AM, Brenner M, Kharitonenkov A, Köster A, Sandusky GE, Sewing S, Treinies I, Zitzer H, Gromada J.
    Diabetes; 2006 Sep 21; 55(9):2470-8. PubMed ID: 16936195
    [Abstract] [Full Text] [Related]

  • 18. New insights into fatty acid modulation of pancreatic beta-cell function.
    Haber EP, Procópio J, Carvalho CR, Carpinelli AR, Newsholme P, Curi R.
    Int Rev Cytol; 2006 Sep 21; 248():1-41. PubMed ID: 16487789
    [Abstract] [Full Text] [Related]

  • 19. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY, Kim YS, Kim CH, Choi HS, Yang J, Park SH, Kim DH, Rhee JK.
    Arch Pharm Res; 2014 May 21; 37(5):671-8. PubMed ID: 23897163
    [Abstract] [Full Text] [Related]

  • 20. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
    Li H, Huang Q, Chen C, Xu B, Wang HY, Long YQ.
    J Med Chem; 2017 Apr 13; 60(7):2697-2717. PubMed ID: 28277660
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 74.